Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris

Maria Leonarda De Rosa, Antonio Giordano, Maria Melfi, Domenico Delia Guardia, Filippina Ciaburri, Franco Rengo

Research output: Contribution to journalArticlepeer-review

Abstract

The antianginal efficacy of 240 mg sustained release verapamil once daily doses and 300 mg diltiazem was studied in 20 normotensive patients with chronic stable angina pectoris, using a randomized, double-blind crossover design. Patients received a blinded therapy of verapamil placebo and diltiazem placebo for six weeks than only sustained-release diltiazem (SRD) for a long-term phase of three weeks, after a two-week placebo baseline period. Symptom-limited bicycle exercise was longer with the verapamil (510±129.9 s) and diltiazem (540±124.6 s) than with placebo at baseline (396± 152.2 s, P

Original languageEnglish
Pages (from-to)27-35
Number of pages9
JournalInternational Journal of Cardiology
Volume63
Issue number1
DOIs
Publication statusPublished - Jan 5 1998

Keywords

  • Diltiazem
  • Exercise hemodynamic effects
  • Stable angina pectoris
  • Verapamil

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Antianginal efficacy over 24 hours and exercise hemodynamic effects of once daily sustained-release 300 mg diltiazem and 240 mg verapamil in stable angina pectoris'. Together they form a unique fingerprint.

Cite this